Our headquarters are located at 14755 Preston Road, Suite 105, Dallas, TX 75254. The main office phone number is (972) 687-7250.
Our common stock is traded on the NASDAQ Capital Market under the symbol SWKH. Our CUSIP number is 78501P203.
Please refer to our latest SEC filings, which are available at investors.swkhold.com/sec-filings and www.sec.gov for available share information.
SWK’s fiscal year end is December 31st.
Computershare
462 South 4th Street
Suite 1600
Louisville, KY 40202
(800) 962-4284
Outside Legal Counsel: Troutman Pepper (875 Third Avenue, New York, NY 10022 | 212-704-6000)
Auditors: BPM LLP
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
SWK Holdings Corporation was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its life science focused specialty finance business. In August 2019, the Company commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business with the acquisition of Enteris BioPharma, Inc.
Tiberend Strategic Advisors is SWK’s investor relations firm. For additional information, please contact:
Jason Rando
Tiberend Strategic Advisors, Inc.
(917) 930-6346
SWK’s officers and directors can be found in the “About SWK” section of our website.
5956 Sherry Lane, Suite 650
Dallas, Texas 75225
Phone: 972.687.7250
Fax: 972.687.7255
For Investors:
investorrelations@swkhold.com
For Capital Alternatives:
inquiries@swkhold.com
For Career Opportunities:
recruiting@swkhold.com